Skip to main content
The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study.
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.
Electrocardiographic consequences of cardiac iron overload in thalassemia major.
Iron chelation adherence to deferoxamine and deferasirox in thalassemia.
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
Hemoglobin H-constant spring in North America: an alpha thalassemia with frequent complications.
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.
HLA type and risk of alloimmunization in sickle cell disease.
Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells.